Objective To explore the effect of a new system for single disease quality management constructed based on 5M1E analysis on improving the assessment rate of clinical TNM staging before tumor treatment. Methods The data of 13 categories of tumor⁃related single disease successfully reported in the single disease quality management system of a cancer specialized hospital in Guangxi from January 1, 2021 to December 31, 2024 were collected. Among them, the data from January 1, 2021 to December 31, 2023 were reported using the old single disease quality management system, and the 5M1E analysis method was used to analyze the root cause of the low TNM staging assessment rate in 5 common categories of tumor⁃related single disease (pulmonary carcinoma, breast cancer, gastric cancer, colon cancer, and thyroid carcinoma), and a new intelligent single disease process quality management system (hereinafter referred to as the new single disease quality management system) was constructed. The new version of the single disease quality management system would be officially operational from January 1, 2024. The following indicators were calculated and compared between 2021 to 2024: the automatic collection rate of single disease quality management system and the assessment rate of clinical TNM staging before tumor treatment of 5 common categories of tumor⁃related single disease, as well as the logical error rate of data reported by the system, the reporting time, and the satisfaction of medical and nursing personnel of 13 categories of tumor⁃related single disease. Results After the official operation of the new single disease quality management system in 2024, the automatic collection rate of the single disease quality management system of 5 common categories of tumor⁃related single disease increased from about 50% to about 90%, and the reporting time of single disease decreased drastically. Various logic error rates and total error rate of data reported by the new single disease quality management system were lower than those of the old single disease quality management system (P<0.05). The pre⁃treatment clinical TNM staging assessment rate of breast cancer, colon cancer and thyroid carcinoma in the new single disease quality management system was higher than that in the old single disease quality management system (P<0.05). The satisfaction of medical and nursing personnel with the new single disease quality management system was higher than that of the old single disease quality management system (P<0.05). Conclusion The new single disease quality management system constructed based on 5M1E analysis can effectively improve the assessment rate of clinical TNM staging before tumor treatment and realize the upgrading of data governance. 

无